CJC/Ipamorelin places two receptor pathways in one formulation. The CJC-1295 No DAC component is associated with GHRH-receptor research; ipamorelin is associated with the ghrelin receptor. That gives researchers a way to ask how separate signaling inputs interact.
What researchers investigate
- GHRH pathway: Investigate the receptor associated with growth hormone-releasing hormone.
- Ghrelin pathway: Examine a different receptor that also participates in endocrine signaling.
- Combined responses: Compare the blend with single components rather than assuming the combination is additive.
What makes it different?
This formulation contains the No DAC version and two separate peptides. It is not the same material as CJC-1295 with DAC.
Research findings describe the materials and conditions studied; they do not predict results in people.

























